RxDoctor Payments Data

Rex Kessler, MD

Endocrinology, Diabetes & Metabolism · Aston, PANPI 1841298023

Payments from drug & device makers

$376in general payments, 2019–2025

Across 16 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$161
  • Merck$39
  • Axsome Therapeutics, Inc.$34
  • Johnson & Johnson$33
  • Bayer$21
  • Inspire Medical Systems, Inc.$21
  • plus $67 from 4 others

What the payments were for

  • Food & beverage$21557%
  • Education$16143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$376 in reported general payments places this provider in the 30th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

See all endocrinology, diabetes & metabolism providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$275,407
Medicare patients
573
Services billed
3,981

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide106$171,800
OzempicSemaglutide90$143,477
JardianceEmpagliflozin105$133,748
Humulin R U-500 KwikpenInsulin Regular, Human82$125,418
Tresiba Flextouch U-200Insulin Degludec82$72,736
FarxigaDapagliflozin Propanediol43$52,156
Fiasp FlextouchInsulin Aspart (Niacinamide)30$49,777
Tresiba Flextouch U-100Insulin Degludec80$49,490
GlyxambiEmpagliflozin/Linagliptin28$43,157
JanuviaSitagliptin Phosphate26$41,138
MounjaroTirzepatide18$29,838
RybelsusSemaglutide13$18,177
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$17,972
Lantus SolostarInsulin Glargine,hum.Rec.Anlog115$13,809
InvokanaCanagliflozin22$12,534

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$15$201,638124 claims
Novo NordiskOzempic, Rybelsus, Novolog Mix 70-30$161$163,061118 claims
MerckJanuvia$39$41,13826 claims
Johnson & JohnsonInvokana$33$12,53422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

Other endocrinology, diabetes & metabolism in Aston

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →